Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNFT 
Genfit S.A. (GNFT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: GNFT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.04
1 Year Target Price $9.04
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.86% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 209.51M USD | Price to earnings Ratio 104.75 | 1Y Target Price 9.04 |
Price to earnings Ratio 104.75 | 1Y Target Price 9.04 | ||
Volume (30-day avg) 1 | Beta 1.28 | 52 Weeks Range 2.55 - 6.42 | Updated Date 09/12/2025 |
52 Weeks Range 2.55 - 6.42 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.13% | Operating Margin (TTM) -293.86% |
Management Effectiveness
Return on Assets (TTM) 1.15% | Return on Equity (TTM) 2.2% |
Valuation
Trailing PE 104.75 | Forward PE 7.27 | Enterprise Value 184015051 | Price to Sales(TTM) 2.96 |
Enterprise Value 184015051 | Price to Sales(TTM) 2.96 | ||
Enterprise Value to Revenue 2.35 | Enterprise Value to EBITDA 18.91 | Shares Outstanding 50002800 | Shares Floating 43768237 |
Shares Outstanding 50002800 | Shares Floating 43768237 | ||
Percent Insiders - | Percent Institutions 0.16 |
Upturn AI SWOT
Genfit S.A.
Company Overview
History and Background
Genfit S.A. is a biopharmaceutical company focused on discovering and developing therapeutic and diagnostic solutions in metabolic and liver diseases. Founded in 1999, it has focused on NASH (nonalcoholic steatohepatitis) and other liver-related disorders.
Core Business Areas
- Therapeutic Development: Focuses on the development and commercialization of therapies for metabolic and liver diseases, particularly NASH. Has historically focused on Elafibranor.
- Diagnostic Solutions: Development of diagnostic tools for early detection and monitoring of liver diseases.
- Drug Discovery: Drug discovery to identify therapeutic options for patients with metabolic and liver disorders.
Leadership and Structure
The company has a board of directors overseeing the management team, headed by the CEO. Details vary over time but follows a standard biopharma structure.
Top Products and Market Share
Key Offerings
- Elafibranor (historical): Elafibranor was Genfit's lead drug candidate targeting NASH. While Phase 3 trials initially showed promise, the drug did not receive regulatory approval and the program was discontinued. Competitors for NASH therapeutics include Madrigal Pharmaceuticals (Resmetirom), Viking Therapeutics, and Akero Therapeutics. Market Share: Prior to discontinuation, Genfit aimed to capture a significant portion of the NASH market.
- NIS4u00ae technology: A diagnostic and monitoring technology for Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH. The current market is still developing. Market share is relatively small but growing as adoption increases. Competitors include other diagnostic companies and emerging biomarker technologies.
- GFT1025: A compound acquired by Genfit, currently in preclinical stage for cholangiopathies. Market share is n/a. Competitors include companies developing treatments for similar liver diseases.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with a focus on innovative therapies for chronic diseases. NASH is a significant unmet medical need.
Positioning
Genfit S.A. aims to be a leader in metabolic and liver diseases. Competes with larger pharma companies and smaller biotech firms.
Total Addressable Market (TAM)
The global NASH market is projected to reach billions of dollars. Genfit aimed to capture a significant portion of this TAM with its pipeline, though its current positioning is evolving.
Upturn SWOT Analysis
Strengths
- Expertise in liver diseases
- Proprietary diagnostic technology
- Strong research and development capabilities
Weaknesses
- Dependence on lead drug candidate (Elafibranor) historically
- Limited commercial infrastructure
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of diagnostic offerings
- New drug development in liver diseases
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles for new drugs
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GILD
- ICPT
- AKRO
- VKTX
- MDGL
Competitive Landscape
Genfit's advantages include expertise in liver diseases, but they compete against larger pharmaceutical companies with more resources.
Major Acquisitions
Versant Ventures-backed company
- Year: 2024
- Acquisition Price (USD millions): 28
- Strategic Rationale: Expand therapeutic pipeline, diversify product range.
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to clinical trial progress and partnerships.
Future Projections: Future growth depends on new drugs progressing through clinical trials.
Recent Initiatives: Recent initiatives include strategic collaborations and refocusing on diagnostic tools and earlier stage assets.
Summary
Genfit S.A. is a biopharmaceutical company specializing in liver diseases. Its historical dependence on Elafibranor created challenges, but it has re-adjusted to focus on diagnostics and new therapies. While the NASH market is promising, Genfit needs to capitalize on strategic partnerships and navigate through competition, maintaining a robust pipeline is crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Press releases
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genfit S.A.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-03-27 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 180 | Website https://www.genfit.com |
Full time employees 180 | Website https://www.genfit.com | ||
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.